Published in Transplantation on November 01, 1992
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood (2013) 3.91
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood (2012) 2.03
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood (2014) 1.14
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood (2007) 1.03
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed) (2013) 1.01
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. Cancer Res (2009) 0.91
Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol (2008) 0.81
The road to purified hematopoietic stem cell transplants is paved with antibodies. Curr Opin Immunol (2012) 0.80
(211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy. Hum Gene Ther (2015) 0.80
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia (2015) 0.79
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. Haematologica (2013) 0.78
Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation. Chimerism (2012) 0.77
Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome. Ther Adv Hematol (2012) 0.77
Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transplant (2014) 0.76
Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy. Bone Marrow Transplant (2017) 0.76
Promising approaches in acute leukemia. Invest New Drugs (2000) 0.75
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11
Bone marrow transplantation for sickle cell disease. N Engl J Med (1996) 4.02
A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet (1979) 4.01
Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med (2001) 3.98
Definition of a common leukocyte cell-surface antigen (Lp95-150) associated with diverse cell-mediated immune functions. J Immunol (1983) 3.70
Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res (2000) 3.64
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59
Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis (1986) 3.31
Monoclonal antibodies to cytomegalovirus: rapid identification of clinical isolates and preliminary use in diagnosis of cytomegalovirus pneumonia. Infect Immun (1982) 3.22
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med (1993) 3.18
Iron Metabolism. Heme Synthesis in Vitro by Immature Erythrocytes. Science (1949) 3.14
Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood (1998) 3.06
Identification of a human T lymphocyte surface protein associated with the E-rosette receptor. J Exp Med (1981) 3.06
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03
Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc (1974) 2.95
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Prognostic nutritional index in gastrointestinal surgery. Am J Surg (1980) 2.66
The clinical impact of increased sensitivity PT and APTT coagulation assays. Am J Clin Pathol (1999) 2.66
Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med (1981) 2.61
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med (1989) 2.61
Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol (1985) 2.46
Reduction of operative morbidity and mortality by combined preoperative and postoperative nutritional support. Ann Surg (1980) 2.43
Nobel laureates' letter to President Bush. Washington Post (2001) 2.43
MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med (1999) 2.41
Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev Infect Dis (1983) 2.39
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36
Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med (1998) 2.36
Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med (1985) 2.30
Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29
Evaluation and management of chylous ascites. Ann Intern Med (1982) 2.26
Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol (1988) 2.24
Direct evidence for a bone marrow origin of the alveolar macrophage in man. Science (1976) 2.23
Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology (1984) 2.19
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood (1998) 2.17
Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet (1972) 2.13
Identification and functional characterization of two distinct epitopes on the human T cell surface protein Tp50. J Immunol (1983) 2.13
Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression. J Immunol (1985) 2.11
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
A prospective analysis interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts. J Infect Dis (1977) 2.10
Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature (1987) 2.04
Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med (1983) 2.03
Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med (1986) 1.99
Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood (1994) 1.98
THE PLACE OF THE BANANA IN THE DIET. Am J Public Health (N Y) (1927) 1.96
A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J Immunol (1986) 1.95
Infection due to Corynebacterium species in marrow transplant patients. Ann Intern Med (1979) 1.94
Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol (1990) 1.91
Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med (1983) 1.89
Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol (1986) 1.89
(F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res (2000) 1.89
The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients. Gastroenterology (1980) 1.88
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (2006) 1.84
A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood (1979) 1.83
Technique for human marrow grafting. Blood (1970) 1.83
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood (1985) 1.81
Mortality hazard functions as related to neutropenia at different times after marrow transplantation. Blood (1996) 1.81
Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med (1975) 1.80
Leukaemic transformation of engrafted human marrow cells in vivo. Lancet (1971) 1.79
Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med (1988) 1.77
Allogeneic marrow grafting for treatment of aplastic anemia. Blood (1974) 1.76
Bone marrow grafts and tolerance. Nature (1986) 1.74
Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol (1988) 1.72
Marrow transplantation for thalassaemia. Lancet (1982) 1.71
PRELIMINARY NOTE CONCERNING THE APPEARANCE OF EXPERIMENTAL DERMATITS (PELLAGRA) IN RATS. Science (1933) 1.69
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet (1995) 1.69
Imaging and treatment of B-cell lymphoma. J Nucl Med (1990) 1.68
Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer (2008) 1.66
Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood (1997) 1.65
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood (1997) 1.64
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood (1987) 1.63
[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging (2003) 1.62
Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass. Metabolism (1977) 1.61
Hickman catheter infections in patients with malignancies. Medicine (Baltimore) (1984) 1.61
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother (2000) 1.60
Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet (1984) 1.60
Myocardial necrosis from direct current countershock. Effect of paddle electrode size and time interval between discharges. Circulation (1974) 1.58